RPL3 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, RPL3 is involved in modulation of cell cycle and apoptosis pathways [42] and serves as a target of Omacetaxine, an anticancer drug used for chronic myeloid leukemia [43].